Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, announces the FDA clearance of the pocket-sized PICO◊ system, a single use Negative Pressure Wound Therapy (NPWT) system. PICO is cleared for use both in a hospital and homecare setting and expands the use of NPWT from the traditional wound care population to include a wider range of patients undergoing orthopaedic surgery, plastic surgery and general surgical procedures. This FDA clearance follows the recent successful launch of PICO in Europe, Canada, and Australia.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51011-smith-nephew-pico-system-fda-approval-npwt
Philips Respironics, a unit of Royal Philips Electronics (NYSE: PHG, AEX: PHI), is introducing its latest advancement in oxygen therapy. SimplyGo is the only portable oxygen concentrator (POC) to offer continuous flow (up to 2 liters per minute) and pulse-dose delivery in a single device weighing 10 pounds or less. With this combination of capabilities, the SimplyGo POC helps homecare providers manage the therapy and lifestyle needs of nearly all oxygen users.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54713-philips-respironics-simplygo-portable-oxygen-concentrator
Approximately 80 million American men and women experience some form of hair loss. Premature balding or thinning hair can often result in a decrease of self esteem. Freedom Laser Therapy of Los Angeles is dedicated to change all that by bringing their iRestore Hair Rejuvenation System to the mass market.
This proven, safe Laser Hair Restoration Technology, otherwise known as phototherapy, is a scientific process providing stimulation to cells in your hair. The 25-year old advanced low-level laser treatment stimulates the scalp, allowing miniaturized and dormant hair follicles to rejuvenate.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54394-freedom-laser-therapy-laser-hair-treatment-regrowth-restoration
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Using a combination of 160 high-resolution tungsten leaves and dramatically faster leaf movement, Elekta’s revolutionary new Agility™* MLC promises a new level of precision and delivery speed in radiation therapy treatments for cancer patients. Elekta recently received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S. medical centers to provide these clinical benefits to their patients with cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55638-elekta-agility-radiation-therapy-radiotherapy-cancer-sbrt
Philips Respironics, a unit of Royal Philips Electronics (NYSE: PHG, AEX: PHI) and a pioneer in science-based sleep solutions, is simplifying the design, fitting and care of full-face masks for sleep apnea patients. With its unique modular design, the new Amara full-face mask further demonstrates Philips’ commitment to developing solutions aimed at improving care and outcomes.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57117-philips-respironics-revolutionary-full-face-mask-sleep-therapy
Breakout star Elle Varner is gearing up for her first nomination for “Best R&B Song” at music’s biggest award show and she is bringing her fans and latest beauty obsession along for the ride. All week long Varner will create her red carpet hair styles with CLEAR SCALP & HAIR BEAUTY THERAPY™ Ultra Shea. She knows strong, beautiful hair is the key to any great style, and it all starts with nourishing the scalp to create the right foundation for beautiful results.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60218-clear-scalp-hair-beauty-therapy-ultra-shea-with-elle-varner
Superstar model, producer, television host and designer Heidi Klum unveiled her secret to strong, beautiful hair last year with the launch of CLEAR SCALP & HAIR BEAUTY THERAPY™, and is now asking women everywhere to join her in the 7 Day Scalp & Hair Challenge for stronger, more beautiful hair in 7 days.
From frequent red carpet appearances to countless hours on set at photo shoots, Klum goes through rigorous daily styling that really takes a toll on her scalp and hair. To nourish her scalp for stronger, more beautiful hair, and to gear up for her next big event, Klum turned to the 7 Day Scalp & Hair Challenge. As part of the challenge, Klum is using CLEAR SCALP & HAIR BEAUTY THERAPY™ shampoo and conditioner daily before styling.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60396-clear-scalp-and-hair-beauty-therapy-heidi-klum-seven-day-challenge
Philips Respironics, a unit of Royal Philips (NYSE: PHG, AEX: PHI) and a pioneer in science-based sleep solutions, today announces a significant advancement in sleep therapy with the commercial release of a first of its kind minimal contact nasal mask – Wisp. Designed to fit more than 98% of sleep apnea patients, Wisp brings distinctive styling and patented technology for a better overall mask experience that may improve patient compliance.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62230-philips-respironics-announces-advancement-in-sleep-therapy-with-wisp
CLEAR MEN SCALP THERAPY™ has signed on as a sponsor for the ESPY awards, airing tonight, showing men how the pros look good both on and off the sports field. The brand enlisted football player Tony Gonzalez who has been in training to be the perfect man on the red carpet, as well as the stage, in his new role as a presenter for the 2013 ESPY Awards on behalf of CLEAR. To get in shape for the show, Tony has been using the “2 in 1” shampoo + conditioners and shampoos designed specifically for men to be sure he keeps his tux flake-free all night long (visible flakes with regular use).
To view Multimedia News Release, go to http://www.multivu.com/mnr/62546-clear-men-scalp-therapy-espn-tony-gonzalez-espy-segment
To mark National Massage Therapy Awareness Week (NMTAW), October 20-26, the American Massage Therapy Association (AMTA) has compiled research that suggests symptoms of stress, anxiety and depression (all associated with mental health) may be alleviated with massage therapy.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63936-amta-massage-therapy-research-roundup-mental-health-benefits
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
